Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.
about
CIViC databaseUpdate on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitorsUnravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsNew developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.Clinical Application of Picodroplet Digital PCR Technology for Rapid Detection of EGFR T790M in Next-Generation Sequencing Libraries and DNA from Limited Tumor Samples.Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer.Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer.Sequencing brain metastases and opportunities for targeted therapies.A novel EGFR-TKI inhibitor (cAMP-H3BO3complex) combined with thermal therapy is a promising strategy to improve lung cancer treatment outcomes.MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib.Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.[Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations
P2860
Q27612411-267F8839-7A44-43F0-9567-D590EA774C30Q28069708-4694ADEA-8E5A-48CC-AAA5-2783518586F2Q28075291-36FF6B51-DE7E-4287-B191-B5B98922D86AQ28075511-937B1818-5AFD-4A84-AF55-8C96A5379F60Q34550460-8A94723A-C1C7-4A5A-A44F-76C6C99BFF57Q36134160-D43498A4-86A4-4FE7-95F1-E6E5859DC4E6Q37000646-E73E068A-4D36-475C-8F7B-B4D87F8F8114Q37085219-3E170E5D-2C18-4679-A1B9-6C5A7794042BQ37726138-07E5A0B4-3AF9-40F8-8F4B-334AD6A08995Q38756349-C7A92007-07A1-4945-8C69-53C49DF0FEECQ39177404-0717D340-789B-482E-9348-813FDC147DD9Q41346859-D03F471B-349B-47B5-85DD-45A0DE7147A6Q47547443-DE8559B4-F0CD-4247-B2F6-EB4BE9FC8412Q49887989-B7FD3935-F3A0-4480-BDAF-60DCD565EE2CQ51741619-5D51A519-3319-4DDA-BCFB-3A3ADC4ED256Q52312436-222F4A59-CCB0-4CF2-9DA3-18B8E6D52386Q58738196-3AA5CF47-7A7E-4736-834B-CC431381340F
P2860
Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Osimertinib Responses After Di ...... ad Been Receiving Rociletinib.
@ast
Osimertinib Responses After Di ...... ad Been Receiving Rociletinib.
@en
Osimertinib Responses After Di ...... ad Been Receiving Rociletinib.
@nl
type
label
Osimertinib Responses After Di ...... ad Been Receiving Rociletinib.
@ast
Osimertinib Responses After Di ...... ad Been Receiving Rociletinib.
@en
Osimertinib Responses After Di ...... ad Been Receiving Rociletinib.
@nl
prefLabel
Osimertinib Responses After Di ...... ad Been Receiving Rociletinib.
@ast
Osimertinib Responses After Di ...... ad Been Receiving Rociletinib.
@en
Osimertinib Responses After Di ...... ad Been Receiving Rociletinib.
@nl
P2093
P3181
P1433
P1476
Osimertinib Responses After Di ...... ad Been Receiving Rociletinib.
@en
P2093
Alice T Shaw
Jeffrey A Engelman
Lecia V Sequist
Matthew J Niederst
Rebecca S Heist
Subba Digumarthy
Zofia Piotrowska
P3181
P356
10.1001/JAMAONCOL.2015.5009
P577
2016-04-01T00:00:00Z